Oral cancer and oropharyngeal cancer
Conditions
Interventions
locally advanced patients:No intervention, observational study
Early and mid-stage patients:No intervention, observational study
Sponsors
Department of Stomatology, Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Signed and dated informed consent form for neoadjuvant treatment (with or without ICIs); 2. Age >= 18 years old, <75 years old; 3. Diagnosed as primary oral cancer or oropharyngeal cancer by the pathology department of our hospital; 4. Local early-to-mid stage oral cavity or oropharyngeal cancer refers to: T1-2NXM0, locally advanced stage refers to: T3-4NXM0, (tumor staging is based on the eighth edition of UICC TNM classification system) 5. The general condition is acceptable, there are no serious diseases of liver, kidney and other important organs, and there are no absolute contraindications for surgery; 6. For men of childbearing potential, use condoms or other methods to ensure that the sexual partner’s contraception is effective; 7. For women of childbearing potential, use highly effective contraceptive measures for at least one month before screening and agree to use this method for contraception during the study period.
Exclusion criteria
Exclusion criteria: 1. Previous cervical lymph node dissection; 2. Combined with primary immune system diseases, primary blood system diseases or primary malnutrition; 3. Taking traditional Chinese medicine or other drugs related to immune function and blood system; 4. Have received radiotherapy, chemotherapy, immunotherapy, targeted therapy and other tumor treatments for head and neck cancer in the past; 5. Unable to comply with experimental research procedures due to geographical, family, social or psychological reasons; 6. Known to be allergic to any of the study drugs involved or their preparation ingredients; 7. Pregnant women; 8. Surgery cannot cure the disease after preoperative induction chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tertiary lymphatic structure;Tumor response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| One-year relapse free survival; | — |
Countries
China
Contacts
Public ContactHaitao He
The Second Affiliated Hospital of Army Medical University
Outcome results
None listed